<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39432667</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-8238</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>17</Day></PubDate></JournalIssue><Title>The Journal of clinical investigation</Title><ISOAbbreviation>J Clin Invest</ISOAbbreviation></Journal><ArticleTitle>Delayed reinforcement of costimulation improves the efficacy of mRNA vaccines in mice.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e183973</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI183973</ELocationID><Abstract><AbstractText>mRNA vaccines have demonstrated efficacy during the COVID-19 pandemic and are now being investigated for multiple diseases. However, concerns linger about the durability of immune responses, and the high incidence of breakthrough infections among vaccinated individuals highlights the need for improved mRNA vaccines. In this study, we investigated the effects of reinforcing costimulation via 4-1BB, a member of the TNF receptor superfamily, on immune responses elicited by mRNA vaccines. We first immunized mice with mRNA vaccines, followed by treatment with 4-1BB costimulatory antibodies to reinforce the 4-1BB pathway at different timepoints post-vaccination. Consistent with prior studies, reinforcing 4-1BB costimulation on the day of vaccination did not result in a substantial improvement of vaccine responses. However, reinforcing 4-1BB costimulation at day 4 post-vaccination, when 4-1BB expression levels were highest, resulted in a profound improvement of CD8 T cell responses associated with enhanced protection against pathogen challenges. A similar clinical benefit was observed in a therapeutic cancer vaccine model. We also report time-dependent effects with OX40, another costimulatory molecule of the TNF receptor superfamily. These findings demonstrate that delayed reinforcement of costimulation may exert an immunologic benefit, providing insights for the development of more effective mRNA vaccines for infectious diseases and cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology-Immunology, Northwestern University, Chicago, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dangi</LastName><ForeName>Tanushree</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Microbiology-Immunology, Northwestern University, Chicago, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awakoaiye</LastName><ForeName>Bakare</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Microbiology-Immunology, Northwestern University, Chicago, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lew</LastName><ForeName>Min Han</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Microbiology-Immunology, Northwestern University, Chicago, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irani</LastName><ForeName>Nahid</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Microbiology-Immunology, Northwestern University, Chicago, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fourati</LastName><ForeName>Slim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Allergy and Immunology, Northwestern University, Chicago, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penaloza-MacMaster</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Microbiology-Immunology, Northwestern University, Chicago, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP2 DA051912</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI187084</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Invest</MedlineTA><NlmUniqueID>7802877</NlmUniqueID><ISSNLinking>0021-9738</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adaptive immunity</Keyword><Keyword MajorTopicYN="N">Immunology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>22</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>14</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39432667</ArticleId><ArticleId IdType="doi">10.1172/JCI183973</ArticleId><ArticleId IdType="pii">183973</ArticleId></ArticleIdList></PubmedData></PubmedArticle>